Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Anafortan Plus is a fixed-dose combination medication developed and marketed by AGP Pharma, primarily used for the management of spasmodic pain. It consists of camylofin dihydrochloride and paracetamol (acetaminophen). Camylofin is a dual-action antispasmodic that functions as a muscarinic acetylcholine receptor antagonist and a phosphodiesterase-4 (PDE4) inhibitor, leading to the relaxation of smooth muscles in the gastrointestinal, biliary, and genitourinary tracts. Paracetamol serves as an analgesic and antipyretic by inhibiting prostaglandin synthesis, primarily within the central nervous system. The Plus variant is distinguished by a higher dose of camylofin (50 mg) compared to the standard Anafortan formulation (25 mg), providing enhanced relief for acute conditions such as renal colic, biliary colic, and severe spasmodic dysmenorrhea.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on camylofin + paracetamol.